Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganwei (HepatoKeeper) and Metformin for NAFLD
NCT06244550Completed
- Sponsor
- Taipei City Hospital
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Randomised, double-blind trial of Ganwei in non-alcoholic fatty liver disease (NAFLD) (4 arms), sponsored by Taipei City Hospital. Primary endpoints: Change in Controlled Attenuation Parameter (CAP) at 24 weeks and Change in Liver Stiffness Measurement at 24 weeks. Started Sep 2021; status: completed.
02
Drugs
Ganwei
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06244550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06244550.